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Abstract
The Src family of protein kinases (SFK) plays key roles in regulating fundamental cellular processes, including
cell growth, differentiation, cell shape, migration, and survival, and specialized cell signals in various malig-
nancies. The pleiotropic functions of SFKs in cancer make them promising targets for intervention. Here, we
sought to investigate the role of microRNA-205 (miR-205) in inhibition of Src-mediated oncogenic pathways in
renal cancer. We report that expression of miR-205 was significantly suppressed in renal cancer cell lines and
tumors when compared with normal tissues and a nonmalignant cell line and is correlated inversely with the
expression of SFKs.miR-205 significantly suppressed the luciferase activity of reporter plasmids containing the 30-
UTR (untranslated region) sequences complementary to either Src, Lyn, or Yes, which was abolished bymutations
in these 30-UTR regions. Overexpression of miR-205 in A498 cells reduced Src, Lyn, and Yes expression, both at
mRNA and protein levels. Proliferation of renal cancer cells was suppressed by miR-205, mediated by the
phospho-Src–regulated ERK1/2 pathway. Cell motility factor FAK (focal adhesion kinase) and STAT3 activation
were also inhibited bymiR-205. Transient and stable overexpression ofmiR-205 in A498 cells resulted in induction
of G0/G1 cell-cycle arrest and apoptosis, as indicated by decreased levels of cyclin D1 and c-Myc, suppressed cell
proliferation, colony formation, migration, and invasion in renal cancer cells. miR-205 also inhibited tumor cell
growth in vivo. This is the first study showing that miR-205 inhibits proto-oncogenic SFKs, indicating a
therapeutic potential of miR-205 in the treatment of renal cancer. Cancer Res; 71(7); 2611–21. 2011 AACR.
Introduction
The Src family of kinases (SFK) are prototypical modular
signaling proteins and the largest family of nonreceptor
protein tyrosine kinases (1–3). They have been shown to be
upregulated in multiple types of human tumors, with Src
activity increasing proportionally to the progressive stages
of the disease (1, 4). Of the 9 family members, c-Src, Fyn, and
Yes are widely expressed in tissues and seem to play an
important role in the regulation of cell adhesion, cell growth,
and differentiation (5). Among the SFKs, Src itself is most
frequently implicated in human cancer, and previous studies
have shown that in mouse models, Src activation is associated
with progression and metastasis in pancreatic (6) and color-
ectal (7) carcinomas. In prostate cancer cells in vitro, inhibi-
tion of SFKs decreases proliferation (8) and, more profoundly,
invasion and migration (9); the latter through selective inhibi-
tion of phosphorylation of Src substrates such as focal adhe-
sion kinase (FAK) and Crk-associated substrate (10). In renal
cancer, Src has been shown to contribute to the appearance of
malignant phenotypes, particularly due to the resistance
against apoptosis by Bcl-xL and angiogenesis stimulated by
Src-STAT3-VEGF signaling (11). The pleiotropic effects of Src
activity are due to the multiple signal pathways engaged by Src
and its accompanying kinases. Src can channel phosphoryla-
tion signals through Ras/Raf/extracellular signal-regulated
kinase 1/2 (ERK1/2) and in certain cells, phophatidylinositol
3-kinase (PI3K)/AKT, pathways. Somewhat selective to SFKs is
their ability to activate STAT3 and b-catenin, which leads to
the activation of c-Myc (12, 13) and, consequently, cyclin D1
(14, 15). Overall, these studies suggest that Src plays pleio-
tropic roles in cancer, often in a cell-dependent manner, and
that Src is a promising target for intervention. Here, we
provide the first demonstration that inhibition of SFKs can
be effectively achieved by microRNA-205 (miR-205) in renal
cancer.
Renal cell carcinoma (RCC) is the seventh most common
cancer in the United States and was predicted to result in
nearly 13,000 deaths in 2009 (16). Surgery is the first line
of treatment with successful resection, often resulting in
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long-term disease-free status. Although the overall survival
rate is more than 60% over 5 years (16), approximately 30% of
patients who have a diagnosis of localized RCC develop
metastatic recurrence (17). These patients have a very poor
prognosis because of the refractory nature of RCC to current
treatment regimens. Therefore, there has been much interest
in the identification of biomarkers for RCC to better predict
cancer development and prognosis.
miRNAs are small, noncoding RNAs that have been found
to regulate expression through targeted repression of gene
transcription and translation. These endogenous silencing
RNAs have been shown to play important roles in develop-
ment and differentiation (18, 19), cellular stress responses
(20), and cancer (21). Specific subsets of miRNAs have also
been shown to be dysregulated in various solid tumors (22,
23). Because of their tremendous regulatory potential and
tissue- and disease-specific expression patterns (24, 25),
there is increasing evidence that miRNA expression profiles
could be indicative of disease risk and burden. Thus, miRNAs
are being assessed as possible biomarkers to aid in the
diagnosis and prognosis of different cancers (26, 27). Here,
we report that miR-205 is significantly downregulated in
renal cancer tissue samples and cell lines. In addition, we
examined the consequences of miR-205 overexpression and
identified the SFKs as direct targets of miR-205 in renal
cancer.
Materials and Methods
Cell culture, plasmids, and transfection
Human RCC cell lines A498, ACHN, Caki-1, and 769-P and
a nonmalignant renal cell line HK-2 were obtained from the
American Type Culture Collection (ATCC) and grown
according to the ATCC protocol (28). Plasmids pEZX-
MT01 miRNA 30-UTR (untranslated region) target expres-
sion clones for Src (HmiT017696-MT01), Lyn (HmiT010935-
MT01), Yes (HmiT018569-MT01), Lck (CS-HmiT010565-
MT01), and miRNA Target clone control vector for pEZX-
MT01 (CmiT000001-MT01; GeneCopoeia), miRNASelect
pEP-miR Null control vector (pEP Null), and miRNASelect
pEP-hsa-miR-205 expression vector (pEP miR-205; Cell Bio-
labs Inc.) were purchased. TaqMan probes for hsa-miR-205
(miR-205), anti–miR-205, and negative controls pre-miR and
anti-miR control (Cont-miR) were purchased from Applied
Biosystems. siRNA duplexes [(Src (Human)-3 unique 27mer
siRNA duplexes (SR304574)] were purchased from Origene
(Origene Technologies, Inc.).
Quantitative real-time PCR
Tissue samples from radical nephrectomy were obtained
from the Veterans Affairs Medical Center, San Francisco, CA.
Total RNA was extracted and assayed for mature miRNAs and
mRNAs, using the TaqMan MicroRNA Assays and Gene
Expression Assays, respectively, in accordance with the man-
ufacturer's instructions (Applied Biosystems). All real time
reactions were run in a 7500 Fast Real Time PCR System
(Applied Biosystems). Relative expression was calculated
using the comparative Ct.
Flow cytometry, cell viability, migratory, clonability,
and invasion assays
Fluorescence-activated cell-sorting (FACS) analysis for
cell cycle and apoptosis was done 72 hours posttransfection,
using nuclear stain DAPI (40,6-diamidino-2-phenylindole) for
cell-cycle analysis or Annexin V-FITC/7-AAD Kit (Beckman
Coulter, Inc.) for apoptosis analysis, according to the man-
ufacturer's protocol. Cell viability was determined at 24, 48,
and 72 hours by using the CellTiter 96 AQueous One Solution
Cell Proliferation Assay Kit (Promega), according to the
manufacturer's protocol. For colony formation assay, cells
were seeded at low density (1,000 cells/plate or 200 cells/
plate) and allowed to grow till visible colonies appeared.
Then, cells were stained with Giemsa, and colonies were
counted. An artificial ''wound'' was created on a confluent
cell monolayer, and photographs were taken after 24 hours
for migration assay. Also, a cytoselect 24-well cell migration
and invasion assay kit (Cell Biolabs, Inc.) was used for
migration and invasion assays, according to manufacturer's
protocol.
Immunoblotting
Immunoblotting was done as described previously (29).
Briefly, protein was isolated from 70% to 80% confluent
cultured cells, using the M-PER Mammalian Protein Extrac-
tion Reagent (Pierce Biotechnology), following the man-
ufacturer's directions. Equal amounts of protein were
resolved on 4% to 20% SDS polyacrylamide gels and trans-
ferred to nitrocellulose membrane. The resulting blots were
blocked with 5% nonfat dry milk and probed with anti-
bodies. All antibodies were obtained from Cell Signaling
Technology, Inc., except c-Myc and cyclin D1, which were
purchased from BD Pharmingen (BD Biosciences). Blots
were visualized using enhanced chemiluminescence (Pierce
Biotechnology).
Luciferase assays
The Src, Lyn, Yes, Lck, and control vectors were pur-
chased from GeneCopoeia and named as Src-30-UTR, Lyn-
30-UTR, Yes-30-UTR, Lck-30-UTR, and empty vector, respec-
tively. Mutated 30-UTR sequences of Src, Lyn, and Yes
complementary to miR-205 were cloned and named Src-
Mut, Lyn-Mut, and Yes-Mut, respectively. For reporter
assays, cells were transiently transfected with wild-type
or mutant reporter plasmid and miR-205 or control-miR.
Firefly luciferase activities were measured by using the Dual
Luciferase Assay (Promega) 24 hours after transfection
and the results were normalized with Renilla luciferase.
Each reporter plasmid was transfected at least 3 times
(on different days), and each sample was assayed in
triplicate.
Stable cell generation and in vivo study
A498 cells were transfected with pEP Null vector and pEP
miR-205 vector (Cell Biolabs) and selected with puromycin (1
mg/mL). pEP miR-205 vector was labeled with red fluorescent
protein. After transfection, cells were observed under a micro-
scope to check for red fluorescence and then selected with a
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cell sorter (BD FACSAria II; BD Biosciences). The sorted cells
were grown in puromycin and real-time quantitative PCR
(qRT-PCR) was done to check the expression of miR-205.
For in vivo studies, 5  106 cells were injected into nude mice
subcutaneously and tumor growth was followed for 28 days.
We also looked at the antitumor effects of miR-205 by local
administration in established tumors. Each mouse was
injected with 7.5  106 cancer cells. Once palpable tumors
developed (average volume ¼ 80 mm3), 6.25 mg of synthetic
miRNA complexed with 1.6 mL siPORT Amine transfection
reagent (Ambion) in 50 mL PBS was delivered 7 times intra-
tumorally in 3-day intervals. Tumor growth was followed for
21 days from first injection. All animal care was in accordance
with the institutional guidelines.
Statistical analysis
All quantified data represent an average of at least triplicate
samples or as indicated. Error bars represent SD of the mean.
Statistical significance was determined by the Student's t test
and 2-tailed P values less than 0.05 were considered signifi-
cant.
Results
miR-205 is downregulated in renal carcinoma, and its
expression is inversely correlated with that of SFKs
Preliminary microarray data revealed that miR-205 was
highly downregulated in renal cancer cell lines compared
with the nonmalignant HK-2 cell line (data not shown). We
validated the microarray data by miRNA qRT-PCR (miR qRT-
PCR) analysis and results confirmed that miR-205 was down-
regulated in all the cancer cell lines (Fig. 1A). To examine the
clinical relevance of miR-205, its expression was analyzed in
carcinoma and normal renal tissue samples. Patients and
tumor characteristics are summarized in Supplementary
Table S1. Almost all carcinoma samples showed significant
downregulation of miR-205 expression with respect to the
normal samples, and an overall lower relative average expres-
sion was observed in carcinoma than in normal samples
(Fig. 1B). These results suggest a potential tumor suppressor
role for miR-205 in renal carcinoma. To identify the potential
targets of miR-205, we used different algorithms that predict
the mRNA targets of a miRNA: miRanda (30), miRNA target
Figure 1. miR-205 expression is
downregulated in renal cancer and
inversely correlated with
expression of Src, Lyn, and Yes. A,
qRT-PCR analysis of miR-205
expression levels in renal cancer
and nonmalignant cell lines. B,
miR-205 expression in a cohort of
renal cancer and normal tissue
samples. C, the miR-205 seed
sequence is complementary to the
30-UTR of Src, Lyn, and Yes. D and
E, Src, Lyn, and Yes mRNA and
protein expression in human renal
cancer and nonmalignant cell
lines. GAPDH, glyceraldehyde
3-phosphate dehydrogenase; *,
P < 0.05.
Src Family of Kinases and miR-205
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predictions (31), TargetScan (32), and PicTar (33). Among the
list of potential targets of miR-205 were mRNAs encoding the
SFKs Src, Lyn, Yes, and Lck. The seed sequence of miR-205 was
complementary to the 30-UTR of these genes (Fig. 1C). To
investigate the correlation between expression of miR-205 and
that of Src, Lyn, and Yes, we measured expression of Src, Lyn,
and Yes at the mRNA and protein levels in the same panel of
cell lines and in individual sets of 12 pairs of tissue samples
(Supplementary Fig. S1). The mRNA and protein expression
levels of these genes were higher than the nonmalignant cell
line (Fig. 1D and E), although the absolute level of expression
varied among different cell lines. The relative miR-205 expres-
sion was higher in the normal tissue samples than in paired
tumor samples, whereas the mRNA expression of Src, Lyn, and
Yes was higher in tumors than in their normal samples
(Supplementary Fig. S1). These data clearly showed an inverse
correlation between the expression of miR-205 and that of Src,
Lyn, and Yes in renal cancer, suggesting that these genes are
targets of miR-205.
The Src family members are direct targets of miR-205
We investigated whether the 30-UTR of Src, Lyn, Yes, and Lck
are functional targets of miR-205 in renal cancer. Transient
transfection of human A498 cancer cells with Src, Lyn, and Yes
30-UTR plasmids along with miR-205 led to a significant
decrease in relative luciferase units when compared with
empty vector and Cont-miR or empty vector and miR-205
(Fig. 2A–D). No significant difference was observed in the case
of Lck-30-UTR (data not shown). The luciferase activity of the
reporter vectors containing a mutated 30-UTR of the respec-
tive genes was unaffected by miR-205 (Fig. 2A–D). These
results indicate that members of the SFKs Src, Lyn, and Yes
(but not Lck) are direct targets of miR-205 in renal cancer.
miR-205 suppresses Src family members and negatively
regulates the Ras/Raf/ERK1/2 pathway in renal
carcinoma
We then determined whether the overexpression of miR-
205 could regulate the levels of Src, Lyn, and Yes mRNA or
protein and alter downstream signaling events. A498 cells
were transfected with miR-205, resulting in miR-205 over-
expression as determined by miR qRT-PCR analysis (Fig. 3A).
miR-205 transient transfection significantly downregulated
Src, Lyn, and Yes at the mRNA level (Fig. 3B). Western blot
analysis also confirmed the downregulation of these genes at
the protein level with miR-205 overexpression (Fig. 3C). These
results support the notion that miR-205 binds to the 30-UTR of
these genes and regulates their expression. Src family kinases
have been shown to be upregulated in multiple types of
human tumors. c-Src itself is widely expressed in tissues
and plays an important role in the regulation of cell adhesion,
cell growth, and differentiation (5). It is frequently implicated
in human cancer, and previous studies have shown that, in
mouse models, Src activation is associated with pancreatic
cancer progression and metastasis (6, 34). Therefore, we
analyzed its role in response to miR-205 overexpression. Src
has been reported to channel phosphorylation signals through
the Ras/Raf/ERK1/2 (35). Src also activates STAT3, a Src target
and key transcriptional factors of c-Myc and cyclin D1 (36, 37),
which leads to their activation (12, 13, 38). Inhibition of Src has
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Figure 2. Src, Lyn, and Yes 30-
UTRs are targets of miR-205. A,
the 30-UTR sequences of Src, Lyn,
and Yes and mutant sequences
that abolished binding. B–D,
luciferase assays showing
decreased reporter activity after
cotransfection of either Src-30-
UTR, Lyn-30-UTR, or Yes-30-UTR
with miR-205 in A498 cells. The
mutant 30-UTRs of either gene had
no effect on reporter activity. *,
P < 0.05.
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been found to inhibit cancer cell proliferation (8), invasion,
and migration (9); the later through selective inhibition of
phosphorylation of Src substrates such as FAK and Crk-
associated substrate (10). To determine whether these effec-
tors are affected by miR-205–mediated suppression of Src,
A498 cells were transfected with miR-205 or Cont-miR. Wes-
tern blot analysis showed reduced levels of the members of the
phospho-ERK1/2 pathway, phospho-STAT3, phospho-FAK, c-
Myc, and cyclin D1 (Fig. 3D) in cells with suppressed phospho-
Src expression following miR-205 overexpression. We next
inhibited the endogenous expression of miR-205 in A498 cells
by transfecting anti–miR-205 (Fig. 3E), an inhibitory oligonu-
cleotide designed specifically to bind and sequester the
mature miR-205 sequence to see whether the expression of
target genes is rescued by inhibiting miR-205. Indeed, the
expression of all the 3 genes was restored at both the protein
and mRNA levels (Fig. 3F) in anti–miR-205-transfected cells.
These data indicate that miR-205 targets Src, which, in turn,
results in suppression of the ERK pathway and the genes
involved in migration/invasion and proliferation.
miR-205 induces apoptosis, cell-cycle arrest, impairs
cell viability, migratory, clonability, and invasive
properties of renal cancer cells
Because Src has been reported to be involved in cancer cell
proliferation (8), invasion, and migration (9), we sought to
determine whether downregulation of Src by miR-205 has
effect on the cell cycle, viability, migratory, or invasion proper-
ties of A498 cancer cells. A significant decrease in cell pro-
liferation was observed over time in A498 cells expressing
miR-205 (Fig. 4A) as compared with cells expressing Cont-miR.
The miR-205–transfected cells also had low colony formation
ability, as both the size and number of foci in miR-205–
expressing cells were suppressed when compared with
Cont-miR–expressing cells (Fig. 4B). To determine whether
miR-205 affects renal cancer cell migration or invasiveness,
wound healing, migration, and invasion assays were con-
ducted. miR-205–overexpressing A498 cells were less profi-
cient than Cont-miR–transfected cells in closing an artificial
wound created over a confluent monolayer (Fig. 4C). Less
absorbance was observed at 560 nmwithmiR-205–transfected
Figure 3. miR-205 suppresses Src, Lyn, and Yes expression and regulates the ERK1/2 pathway. A, relative miR-205 expression level. B and C, qRT-PCR
and Western blot analysis showing decreased Src, Lyn, and Yes expression. D, Western analysis showing a decrease in the ERK1/2 pathway, cyclin D1,
and c-Myc and a decrease in phospho-STAT3 and FAK in miR-205–transfected A498 cells. E, relative miR-205 expression in anti–miR-205 transiently
transfected A498 cells. F, Western blot and qRT-PCR analysis showing that Src, Lyn, and Yes expression was rescued in cells transfected with anti–miR-205.
MAPK, mitogen activated protein kinase; MEK, MAP/ERK kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Src Family of Kinases and miR-205
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cells than Cont-miR–tranfected cells in the migration assay
(Fig. 4C). miR-205 overexpression also significantly reduced
the invasiveness of A498 cells (Fig. 4D). FACS analysis revealed
that reexpression of miR-205 leads to a significant increase
(10%  3%) in the number of cells in the G0/G1 phase of the
cell cycle whereas the S-phase population decreased from 15%
 4% to 5%  3%, suggesting that miR-205 causes a G0/G1
arrest in miR-205–transfected A498 cells compared with a
nonspecific miRNA control (Cont-miR; Fig. 4E). FACS analysis
for apoptosis was conducted using Annexin V-FITC-7-AAD
dye. The percentage of total apoptotic cells (early apoptotic þ
apoptotic) was significantly increased (14% 3%) in response
to miR-205 transfection compared with Cont-miR (4%  2%),
with a corresponding 10%  4% decrease in the viable cell
population (Fig. 4F). All the functional assays were confirmed
in the 769-P cell line, which is from the same tumor type as
A498 cells, and the results were consistent (Supplementary
Fig. S2). These results indicate that suppression of phospho-
Src by miR-205 inhibits renal cell proliferation, invasion, and
migration by inhibiting phosphorylation of FAK, a Src sub-
strate, c-Myc, a Src target gene (39), and cyclin D1, the rate
limiting factor for cellular proliferation (40, 41).
Src inhibition by siRNA mimics miR-205 reconstitution
in renal cancer and attenuation of miR-205 in
nonmalignant cells increases proliferation, migration,
and invasion
Phenocopy experiments inhibiting Src expression by siRNA
were also conducted (Fig. 5). We initially tested 3 siRNAs to
achieve 80% to 90% Src gene knockdown and confirmed the
results at the mRNA and protein levels (Fig. 5A). Then we
selected one siRNA (S-1) for further experiments. Our results
showed that siRNA inhibition of Src caused decreased cell
viability (Fig. 5B), migratory, and invasive (Fig. 5C) capability
of A498 cancer cells. We also observed a G0/G1 cell-cycle arrest
(14%), whereas there was a decrease of 11% in S-phase cell
population (Fig. 5D). Almost 5% of the cells were in the
apoptotic fraction in Src siRNA–transfected cells compared
Figure 4. Transient transfection of miR-205 inhibits renal cancer cell proliferation, colony formation, migration, and invasion and induces apoptosis and cell-
cycle arrest in A498 cells. A, proliferation of A498 cells after miR-205 transfection was significantly reduced compared with Cont-miR. B, miR-205
overexpression significantly inhibits colony formation of A498 cells. C, wound healing andmigration assays of A498 cells transfectedwithmiR-205. D, invasion
assay shows a significant decrease in the number of invading A498 cells transfected with miR-205. E, cell-cycle analysis showing an increase in the G0/G1
phase of A498 cells overexpressing miR-205. F, apoptosis assay showing induction of apoptosis by miR-205. *, P < 0.05.
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with nonspecific control (Fig. 5D). These results provide
evidence that inhibition of Src by miR-205 reconstitution is
responsible for the observed phenotype in renal cancer cells.
We also knocked down the expression of miR-205 in HK-2 cells
that expressed high levels of miR-205 (Fig. 6A) and determined
its effect on cell growth, migration, and invasion. Our results
showed that cells transfected with anti–miR-205 showed
increased proliferation (Fig. 6B), migration (Fig. 6C), and
invasion (Fig. 6D) compared with control anti-miRNA. These
results show that miR-205 is an important tumor suppressor
Figure 5. Knockdown of Src by siRNA. A, relative SrcmRNA levels assessed by qRT-PCR in A498 cells transfected with 50 nmol/L siRNA duplexes (S-1, S-2,
and S-3) and a nonsilencing siRNA duplex (control). Src protein levels were assessed byWestern blot in A498 cells transfected with 50 nmol/L siRNA duplexes
and a nonsilencing siRNA duplex. B, proliferation of A498 cells after S-1 transfection was significantly reduced compared with control. C, a significant
decrease was observed in the migratory capability of A498 cells after siRNA (S-1) transfection compared with control. Invasion assay shows a significant
decrease in the number of invading A498 cells transfected with S-1. D, cell-cycle analysis showing an increase in the G0/G1 phase of A498 cells transfected
with S-1. Apoptosis assay showing induction of apoptosis after Src knockdown by S-1. *, P < 0.05. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Src Family of Kinases and miR-205
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miRNA in renal cancer and attenuation of this miRNA in
overexpressing nonmalignant renal cells increases their pro-
liferative, migratory, and invasive capability.
miR-205 inhibits tumor growth in vivo
The antitumor effect of miR-205 stably transfected in A498
cells was determined by carrying out phenocopy experiments
in vitro (Supplementary Fig. S3) and confirmed by in vivo
experiments. Stable overexpression of miR-205 dramatically
suppressed tumor growth in vivo on subcutaneous injection
into nude mice when compared with cells expressing control
vector (Fig. 7A). We further checked the expression of miR-205
or Src, Lyn, and Yes in 8 harvested tumors, 4 from pEP Null
control group, and 4 from pEP miR-205 group. Our results
showed that miR-205 expression was significantly high, with a
corresponding significant decrease in the target gene expres-
sion in tumors that had pEP miR-205 compared with the pEP
Null control (Supplementary Fig. S4A and B). Because over-
expression of miR-205 inhibited cell growth in vitro, we
conducted an additional experiment to check the antitumor
effect of miR-205 after local administration in established
A498 tumors. Indeed, the tumor volume regressed from 81
to 5 mm3 with miR-205 compared with Cont-miR, in which
tumor volume increased from 80 to 306 mm3 (Fig. 7B). These
results show that miR-205 suppressed cancer growth both
in vitro and in vivo.
Discussion
In this study, we provide evidence that miR-205 interdicts
SFK pathways by inhibiting their expression at both themRNA
and protein levels. Our results show that Src inhibition by
miR-205 leads to growth suppression and cell-cycle arrest in
renal cancer and are accompanied by inactivation of ERK1/2
and downregulation of c-Myc and cyclin D1. FAK and STAT3
phosphorylation were also decreased by diminished Src
Figure 6. Attenuation of miR-205
expression by anti–miR-205 in
HK-2 cells. A, relative miR-205
expression. B, HK-2 cells had
increased proliferation after anti–
miR-205 transfection compared
with the anti–miR control (Cont-
miR). C and D, migration and
invasion assays. *, P < 0.05.
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activity, leading to significantly reduced cell migration and
invasion.
Expression of miR-205 in cancer is controversial because it
has been found to be either upregulated (42) or downregulated
(43) in tumors. In this study, we examined the expression
pattern and functional significance of miR-205 in renal cancer.
We found miR-205 to be significantly downregulated in tumor
samples when compared with adjacent normal samples. The
downregulation of miR-205 expression was also observed in
RCC cell lines when compared with a nonmalignant cell line.
This is consistent with a previous microarray analysis of 27
samples of kidney cancer tissues that showed downregulation
of miR-205 (42). The significant suppression of miR-205
expression in tumors and cancer cell lines suggests a tumor
suppressor role in renal carcinoma. However, neither the
functional role nor the targets of miR-205 in renal cancer
have been previously defined.
An obstacle to understanding miRNA function has been the
relative lack of experimentally validated targets. To determine
potential targets of miR-205 action, several in silico algorithms
were utilized to identify SFKs as putative targets of miR-205.
The SFKs play an important role in the regulation of cellular
proliferation and cell-cycle progression (5). Our results indi-
cate an inverse correlation between expression of miR-205 and
that of phospho-Src, Lyn, and Yes in cell lines and tissues
samples. We showed that miR-205 directly targets the 30-UTR
of phospho-Src, Lyn, and Yes, as its overexpression was
associated with suppression of luciferase activity. In addition,
a significant downregulation of phospho-Src, Lyn, and Yes
protein and mRNA levels was observed after miR-205 over-
expression, indicating that phospho-Src, Lyn, and Yes mRNAs
are targets of miR-205.
Because of the reported importance of phospho-Src in renal
cancer (11), we further characterized its role in response to
miR-205. It has been reported that Src is involved in multiple
signaling pathways including Ras/Raf/ERK1/2, PI3K/AKT,
b-catenin/c-Myc/cyclin D1, and FAK/p130CAS/MMP-9 that
induce growth, survival, and migration in various types of
cancer cells (35). We observed that inhibition of phospho-Src
by miR-205 overexpression reduced signaling via the ERK1/2
pathway. A previous study by Chang and colleagues (35) and
others (44) have shown that Src inhibition by small molecule
inhibitors induced apoptosis and cell-cycle arrest at the G0/G1
phase of the cell cycle in prostate cancer cell lines. Our results
revealed that inhibition of phospho-Src by miR-205 overex-
pression induced apoptosis and G0/G1 arrest in renal cancer
cells. This effect on the cell cycle prompted us to study the
effect on c-Myc, a Src target gene (39), cyclin D1, the rate
limiting factor for cellular proliferation (41), and phospho-
STAT3, a Src target and key transcriptional factor for c-Myc
and cyclin D1 (37). We found that all these genes were
downregulated at the protein level. Our results indicate that
miR-205 inhibited renal cell migration and invasion and also
downregulated phospho-FAK, a Src substrate in renal cancer
Figure 7. miR-205 inhibits tumor
growth in vivo. A, tumor volume
following subcutaneous injection
of stable A498 cells expressing
miR-205 was significantly
reduced. B, tumor volume
following intratumoral injection of
Cont-miR or miR-205 precursor
into established tumors. *, P <
0.05.
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cells. Inhibition of Src has been found to decrease the invasion
and migration of prostate cancer cells (9) through selective
inhibition of phosphorylation of Src substrates, such as FAK.
To determine whether Src inhibition is responsible for the
phenotype observed after miR-205 reconstitution, we con-
ducted phenocopy experiments inhibiting Src expression by
siRNA. Our results showed that inhibition of Src was respon-
sible for decreased cell viability, migratory, and invasive cap-
ability of A498 cancer cells. We also observed a G0/G1 cell-
cycle arrest (14%) whereas there was a decrease of 11% in S-
phase cell population. Almost 5% apoptotic cells were
observed in Src siRNA-transfected cells compared with non-
specific control. These results prove that tumor-suppressive
effect of miR-205 is mediated by Src inhibition in renal caner.
We further attenuated miR-205 expression in nonmalignant
HK-2 cells that expressed higher levels of miR-205 and deter-
mined its effect on cell growth, migration, and invasion. Our
results showed that cells transfected with anti–miR-205
showed more proliferation, migration, and invasion than
those transfected with control anti-miRNA. These results
indicate that miR-205 is important tumor suppressor miR
in renal cancer and attenuation of this miRNA in overexpres-
sing nonmalignant renal cells increases their proliferative,
migratory, and invasive capability.
The antiproliferative effects of miR-205 observed in this
study, mediated by suppression of phospho-Src and down-
stream target genes, were confirmed following stable over-
expression of miR-205 in A498 cells. In vivo studies showed a
striking reduction in subcutaneous tumor cell growth in mice
injected with stable A498 cancer cells overexpressing miR-205.
Furthermore, results from local administration of miR-205 in
established tumors revealed a dramatic regression of tumor
growth compared with the Cont-miR. In conclusion, our study
shows an important tumor suppressor role for miR-205 in
renal cancer.
The SFKs are essential for many important tumorigenic
phenotypes including proliferation, invasion, migration,
epithelial-to-mesenchymal transition (5, 45), apoptosis, survi-
val, angiogenesis, etc. Thus, the activity of SFKs increase in
progressive stages of tumors, with the highest activity
observed in metastatic lesions (46). Increasing evidence from
molecular and pharmacologic studies suggests that inhibition
of Src, the prototype SFK member, inhibits tumor function
associated with metastasis, including migration, invasion, and
expression of the proangiogenic molecules, such as interleu-
kin-8 and VEGF (47). In addition, recent studies indicate that
Src plays critical roles in host cells in the tumor microenvir-
onment and the tumor cells that contribute to metastasis (4).
Several studies have shown that Src-mediated phosphoryla-
tion of VE-cadherin, a cell adhesion molecule that is essential
to vascular cell-to-cell junctional integrity, directly leads to
increased vascular permeability, thus facilitating intravasation
and extravasation of migratory tumor cells (48). Thus, Src
plays pleiotropic roles in cancer, making it a promising
therapeutic target for intervention. Our study is the first report
showing that miR-205 inhibits the proto-oncogenic SFKs,
indicating the therapeutic potential of miR-205 in the treat-
ment of renal cancer.
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